HUE053949T2 - N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok - Google Patents

N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Info

Publication number
HUE053949T2
HUE053949T2 HUE10739701A HUE10739701A HUE053949T2 HU E053949 T2 HUE053949 T2 HU E053949T2 HU E10739701 A HUE10739701 A HU E10739701A HU E10739701 A HUE10739701 A HU E10739701A HU E053949 T2 HUE053949 T2 HU E053949T2
Authority
HU
Hungary
Prior art keywords
protofibrils
oligomers
terminally truncated
antibodies selective
truncated amyloid
Prior art date
Application number
HUE10739701A
Other languages
English (en)
Hungarian (hu)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda Soederberg
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of HUE053949T2 publication Critical patent/HUE053949T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE10739701A 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok HUE053949T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
HUE053949T2 true HUE053949T2 (hu) 2021-08-30

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10739701A HUE053949T2 (hu) 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Country Status (16)

Country Link
US (2) US20120100129A1 (cg-RX-API-DMAC7.html)
EP (2) EP3892633A1 (cg-RX-API-DMAC7.html)
JP (3) JP2012532094A (cg-RX-API-DMAC7.html)
AU (1) AU2010267640B2 (cg-RX-API-DMAC7.html)
CA (1) CA2765602C (cg-RX-API-DMAC7.html)
CY (1) CY1124034T1 (cg-RX-API-DMAC7.html)
DK (1) DK2448968T3 (cg-RX-API-DMAC7.html)
ES (1) ES2864049T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210611T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053949T2 (cg-RX-API-DMAC7.html)
LT (1) LT2448968T (cg-RX-API-DMAC7.html)
PL (1) PL2448968T3 (cg-RX-API-DMAC7.html)
PT (1) PT2448968T (cg-RX-API-DMAC7.html)
SI (1) SI2448968T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100237T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011001366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP2325209A3 (en) 2006-03-23 2011-08-03 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
ES2661925T3 (es) 2010-02-26 2018-04-04 Bioarctic Ab Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías
AU2012228236B2 (en) * 2011-03-16 2016-10-27 Vivoryon Therapeutics N.V. Diagnostic antibody assay
JO3537B1 (ar) 2014-07-10 2020-07-05 Bioarctic Neuroscience Ab أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
SG10201912842VA (en) 2016-07-14 2020-02-27 Bioarctic Ab Brain delivery protein
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2019309938A1 (en) 2018-07-24 2021-03-11 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
EP3998280A4 (en) * 2019-07-08 2023-06-21 TERUMO Kabushiki Kaisha HYBRIDOME AND METHOD FOR PRODUCTION, MONOCLONAL ANTIBODY AND METHOD FOR PRODUCTION
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
PH12022552829A1 (en) 2020-06-26 2023-06-14 Bioarctic Ab Alpha-synuclein protofibril-binding antibodies
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
WO2023034230A1 (en) 2021-08-30 2023-03-09 Eisai R&D Mangement Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
AU2023410175A1 (en) 2022-12-22 2025-07-03 Bioarctic Ab Antibody which binds to abetape3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
DE60016227T2 (de) * 1999-08-04 2005-12-15 Northwestern University, Evanston Globularer aufbau vom amyloid-beta- protein und deren verwendungen
EP1309341A2 (en) * 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) * 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
JP4633788B2 (ja) * 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
TWI355389B (en) * 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
EP2325209A3 (en) * 2006-03-23 2011-08-03 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
PT2207568T (pt) * 2007-11-16 2017-09-01 Univ Rockefeller Anticorpos específicos para a forma de protofibrilha da proteína beta-amilóide
EP3470079A1 (en) * 2008-04-29 2019-04-17 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders

Also Published As

Publication number Publication date
DK2448968T3 (da) 2021-04-12
WO2011001366A1 (en) 2011-01-06
AU2010267640A1 (en) 2012-01-19
JP2017197531A (ja) 2017-11-02
SMT202100237T1 (it) 2021-05-07
EP2448968B1 (en) 2021-01-27
JP6884025B2 (ja) 2021-06-09
CY1124034T1 (el) 2022-05-27
ES2864049T3 (es) 2021-10-13
EP2448968A1 (en) 2012-05-09
JP2019218362A (ja) 2019-12-26
CA2765602C (en) 2021-05-25
PL2448968T3 (pl) 2021-09-13
SI2448968T1 (sl) 2021-07-30
CA2765602A1 (en) 2011-01-06
EP3892633A1 (en) 2021-10-13
US20120100129A1 (en) 2012-04-26
HRP20210611T1 (hr) 2021-05-28
PT2448968T (pt) 2021-04-30
JP2012532094A (ja) 2012-12-13
AU2010267640B2 (en) 2015-03-05
US20230295283A1 (en) 2023-09-21
LT2448968T (lt) 2021-05-10

Similar Documents

Publication Publication Date Title
HUE053949T2 (hu) N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok
PT2406284T (pt) Anticorpos anti-bcma
EP2406399A4 (en) MIRAC PROTEINS
DOS2010000009S (es) Botella
DK2480734T3 (da) Skinnesystem
DOS2010000006S (es) Botella
EP2448809A4 (en) CHANNEL SYSTEM
UY3958Q (es) Botella
BRPI1008979A2 (pt) meio de fixação
ITPD20090053U1 (it) Paradordi per banchine
ES1071736Y (es) Botella
DE112010001522A5 (de) Mobile förderbrücke
DE112010001392A5 (de) Vibrator
ITCT20090003U1 (it) Telepass -2 per non udenti
TH93312B (th) ขวด
FR2951765B1 (fr) Paumelle pour persiennes
FI20090460A0 (fi) Määritysmenetelmä
FI20090461A0 (fi) Määritysmenetelmä
FI20096331A0 (fi) Antibodin käyttö
DOS2009000147S (es) Botella
DOS2009000212S (es) Botella
CR10687S (es) Viga bloque
TH93146B (th) ขวด
TH119057B (th) ขวด
UA19420S (uk) Пляшка